Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of AMG 531 in thrombocytopenic myelodysplastic syndromes
NL-OMON31052Phase 2Not yet recruiting
- Sponsor
- Amgen
- Start
- Sep 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in myelodysplastic syndrome (MDS), sponsored by Amgen. Primary endpoint: Incidence of all adverse events. Planned start Sep 2007; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON31052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31052.